Sanofi and Teva's Collaboration Ignites Competition in IBD Drug Market
Sanofi has secured a deal worth up to $1.5 billion with Teva for the development and launch of Teva's anti-TL1A antibody. Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. This deal adds fuel to the competition against Merck and Roivant, who are also developing anti-TL1A treatments.